Kodiak Sciences, Inc. KOD

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Its latest study suggested its drug candidates improved eyesight for patients with wet macular degeneration as much as the leading treatment.

Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.

Kodiak Sciences Inc. (NASDAQ:KOD) saw its share price nearly triple on Monday to a near five-year high, as investors loaded positions to cheer strong clinical trial results for its wet AMD treatment candidate. In intraday trading, the stock soared by as much as 196 percent before trimming gains to finish the session just up by […]

FEATURE Stocks fell Monday as waning peace talks between the U.S. and Iran drove oil prices and bond yields higher. Nvidia rose 1.7%. The chip maker said it would launch the largest-ever U.S. stock buyback of $150 billion, bringing the total buyback authorization to $235 billion.

Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.

Healthcare stocks rose late Monday afternoon with the NYSE Healthcare Index and the State Street Hea

Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.

Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement. Both experimental drugs demonstrated...

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo.

Key TakeawaysKodiak Sciences shares jumped about 141% after its drug Zenkuda met its primary endpoint in the pivotal Phase 3 DAYBREAK trial in wet AMD. Zenkuda’s edge is durability: it matched aflibercept on vision gains while 54% of its patients were on 6-month dosing under strict retreatment rules.

Kodiak Sciences shares saw their biggest ever single-day gains after the company posted positive Phase 3 data for 2 therapies targeting wet age-related macular degeneration.